Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN HUFFAKER

Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family

NPI
1558824292
CMS profile
10420309
Location
VENICE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$15.92

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $15.92 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $15.92 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN HUFFAKER

NPI 1558824292 · CMS profile ID 10420309

Physician Assistants & Advanced Practice Nursing Providers / Nurse Practitioner / Family

VENICE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558824292?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN HUFFAKER, NPI 1558824292, CMS profile ID 10420309. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558824292?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN HUFFAKER, NPI 1558824292, CMS profile ID 10420309. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558824292?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN HUFFAKER, NPI 1558824292, CMS profile ID 10420309, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1558824292?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $15.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $15.9208/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012265091 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $20.89 1
PY2023 $15.92 1
PY2024 $43.96 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,296,431.31 32
PY2024 Recipient $17,997.60 4
PY2024 Principal investigator $3,104,411.55 55
PY2023 Recipient $147.50 2
PY2023 Principal investigator $3,646,147.55 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $53,465.00 12/09/2024 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137358997
Principal investigator 1 Eli Lilly and Company $1,200.00 12/09/2024 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137359459
Principal investigator 1 Vanda Pharmaceuticals Inc. $950.00 11/29/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133925876
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,182.00 11/29/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133925880
Principal investigator 1 Novo Nordisk AS $100.00 10/31/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096643224
Principal investigator 1 Novo Nordisk AS $744.23 10/31/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096653472
Principal investigator 1 Novo Nordisk AS $1,500.00 10/31/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096704370
Principal investigator 1 Eli Lilly and Company $2,606.65 10/28/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC ASSOCIATES OF SOUTHWEST FL PA
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137363735
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,890.00 10/25/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133925559
Principal investigator 1 Vanda Pharmaceuticals Inc. $500.00 10/11/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133925435
Principal investigator 1 Vanda Pharmaceuticals Inc. $250.00 10/11/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133925443
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,278.00 10/04/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133925383
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,268.00 10/04/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133925387
Principal investigator 1 Eli Lilly and Company $42,850.65 10/02/2024 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137358995
Principal investigator 1 Vanda Pharmaceuticals Inc. $15,360.00 09/26/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133925219
Recipient Eli Lilly and Company $7,161.00 09/24/2024 Covered Recipient Non-Physician Practitioner ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137349675
Recipient Eli Lilly and Company $10,824.00 09/24/2024 Covered Recipient Non-Physician Practitioner A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137349805
Principal investigator 1 Novo Nordisk AS $22.41 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096636138
Principal investigator 1 Novo Nordisk AS $4.89 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096638687
Principal investigator 1 Novo Nordisk AS $6.50 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096644297
Principal investigator 1 Novo Nordisk AS $10.39 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096667061
Principal investigator 1 Novo Nordisk AS $2.13 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096676146
Principal investigator 1 Novo Nordisk AS $22.14 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096687222
Principal investigator 1 Novo Nordisk AS $7.38 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096692467
Principal investigator 1 Novo Nordisk AS $6.39 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096693546
Principal investigator 1 Novo Nordisk AS $31.17 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096701666
Principal investigator 1 Novo Nordisk AS $14.67 08/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096702232
Principal investigator 1 Eli Lilly and Company $3,963.01 08/05/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC ASSOCIATES OF SOUTHWEST FL PA
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137362915
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,364.00 07/29/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133924792
Principal investigator 1 Novo Nordisk AS $3,580.36 07/22/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096708854
Principal investigator 1 Biogen, Inc. $14,358.00 07/15/2024 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 2, randomized, multicenter, two-arm, open-label study to compare the pharmacodynamics, safety, and tolerability of subcutaneous versus intravenous administration of Aducanumab (BIIB037) in participants with Alzheimer's disease No dispute reported 06/30/2026 1104839853
Principal investigator 1 Vanda Pharmaceuticals Inc. $500.00 07/08/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133924557
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,111.00 07/08/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133924581
Principal investigator 1 Novo Nordisk AS $1,223.60 06/21/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096649470
Recipient Eli Lilly and Company $8.40 06/14/2024 Covered Recipient Non-Physician Practitioner A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137349917
Recipient Eli Lilly and Company $4.20 06/14/2024 Covered Recipient Non-Physician Practitioner ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137350249
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,175.00 06/07/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133924384
Principal investigator 1 Novo Nordisk AS $150.00 05/29/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096687254
Principal investigator 1 Vanda Pharmaceuticals Inc. $16,600.00 05/24/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133924151
Principal investigator 1 Vanda Pharmaceuticals Inc. $875.00 05/24/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133924155
Principal investigator 1 Novo Nordisk AS $6.50 05/23/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096626773
Principal investigator 1 Novo Nordisk AS $5.05 05/23/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096632256
Principal investigator 1 Novo Nordisk AS $823.08 04/30/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096641109
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,913.00 04/12/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133923747
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,428.00 03/22/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133923414
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,575.00 02/27/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133923080
Principal investigator 1 Eli Lilly and Company $33.60 02/19/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC ASSOCIATES OF SOUTHWEST FL PA
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137364337
Principal investigator 1 Eli Lilly and Company $4,300.00 02/05/2024 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A STUDY OF DONANEMAB (LY3002813) COMPARED WITH ADUCANUMAB IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 4) No dispute reported 06/30/2026 1137359221
Principal investigator 1 Eli Lilly and Company $4,364.09 01/25/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC ASSOCIATES OF SOUTHWEST FL PA
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137363087
Principal investigator 1 Novo Nordisk AS $2,074.80 01/24/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC RESEARCH CENTER
NN6535-4725 No dispute reported 06/30/2026 1096626756
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,428.00 01/24/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AN OPEN LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF TRADIPITANT IN PARTICIPANTS AFFECTED BY MOTION SICKNESS No dispute reported 06/30/2026 1133922957
Principal investigator 1 Eli Lilly and Company $112,162.00 01/09/2024 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137358517
Principal investigator 1 Eli Lilly and Company $5,733.40 01/09/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC ASSOCIATES OF SOUTHWEST FL PA
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137363537
Principal investigator 1 Eli Lilly and Company $10,617.84 01/08/2024 Non-covered Recipient Entity
NEUROPSYCHIATRIC ASSOCIATES OF SOUTHWEST FL PA
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137364183
Principal investigator 1 Biogen, Inc. $37,506.00 01/05/2024 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1104838072
Principal investigator 1 Biogen, Inc. $291,441.00 01/03/2024 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 1104839630
Principal investigator 1 Eli Lilly and Company $1,502,840.62 01/02/2024 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137357741
Principal investigator 1 Eli Lilly and Company $301,547.00 01/02/2024 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137358515
Principal investigator 1 Eli Lilly and Company $637,440.00 01/02/2024 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137359463